Prognostic Model of Rituximab in the Treatment of MN

Inclusion Criteria

• •1. Aged 18-75 years, the patient was diagnosed as idiopathic membranous nephropathy or anti phospholipase A2 receptor (PLA2R) antibody positive by renal puncture biopsy, and the clinical data were complete;
• •2. According to the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines in 2020, it conforms to the medium and high risks in the risk level of progression of renal function loss.
• •3. In general, they are in good condition, have a good understanding of their own conditions and physical conditions, have self-awareness, and can communicate well with others;
• •4. Volunteer to participate in the study, understand the significance of this experiment and the indicators to be measured, and sign the informed consent form.